OFF-PUMP CAB TO EVALUATE THE EFFECT OF BOTOX? ON ARTERIAL GRAFTS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 在人类，冠状动脉搭桥术(CABG)是使用患者的胸内动脉(ITA)或桡动脉(RA)作为搭桥管道。使用这些动脉是因为与其他血管相比，这些动脉显示出长期的通畅性优势。然而，在手术期间以及手术后的几天或几周内，这些移植物可能会经历突然的严重痉挛，可能会导致缺血、心肌梗死或猝死。手术期间和手术后都会给药，以防止痉挛的可能性，但它们的作用时间不长，需要频繁重复服药。此外，这些药物有时会有严重或麻烦的副作用，使它们不受欢迎，有时对患者来说是危险的。理想的药物应该是在手术时只需对移植物进行一次应用，没有全身或副作用，并且持续数周或数月。 A型肉毒梭菌毒素(Botox)是一种具有这些有利特性的商业化药物。虽然它通常用于整形和普通外科手术，但我们对文献的回顾显示，没有公开的数据表明它可以阻断冠状动脉旁路移植的痉挛。有一份动物研究报告表明，肉毒杆菌可以减少子宫动脉痉挛，而在一项单一的人类研究中，雷诺氏病(严重的手指动脉痉挛)患者在注射肉毒杆菌后5分钟内痉挛缓解。这是我们的附加假设，即肉毒杆菌毒素可能在人类冠脉搭桥术中有用。 我们的第一步是进行体外研究，看看肉毒杆菌是否能阻止血管痉挛。我们刚刚完成了对多段废弃的人胸内动脉的体外肌电图测试，结果表明，与对照组相比，肉毒杆菌显著阻止了痉挛的倾向。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. In humans, coronary artery bypass grafts (CABG) are performed using the patients internal thoracic artery (ITA) or the radial artery (RA) for the bypass conduits.. These arteries are used because of demonstrated long term patency superiority to other vessels. However during surgery and for several days or weeks after the surgery, these grafts can experience sudden severe spasm that can cause ischemia, myocardial infarction, or sudden death. Drugs are given during the surgery and afterwards to prevent the possibility of spasm but they are not long acting and require frequent repeated dosing. Additionally the drugs sometimes have serious or troublesome side effects that make them unpopular and sometimes dangerous for the patients. The ideal drug would be one that required only one application to the graft at the time of surgery, had no systemic or side effects, and lasted for weeks or months. Clostridium botulinum toxin type A (Botox) is a commercially available drug that has those favorable characteristics. Though it is commonly used in plastic and general surgery, our review of the literature reveals no published data on the specific use to block coronary bypass graft spasm. There is one report in animals that Botox reduced uterine artery spasm and a single human study in which patients with Raynaud's disease (severe spasm of the arteries to the fingers) had the spasm relieved within 5 minutes of injection with Botox. It is our additional hypothesis that Botox may be useful in CABG surgery in humans. Our first step was to perform in vitro studies to see if Botox would block vessel spasm. We just completed in vitro myography tests of multiple segments of discarded human internal thoracic artery and have shown that Botox significantly blocks the tendency for spasm when compared to controls.